Plain-English translation of NCT06991322 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new device called the A-FLUX Coronary Sinus Reducer, which is implanted during a minimally invasive procedure. The device is designed to help people who have ongoing chest pain caused by coronary microvascular dysfunction—a condition where the tiny blood vessels in the heart don't deliver blood as well as they should. This is an early-stage study looking at whether the treatment is safe and effective for people who continue to have symptoms despite taking heart medications.
Many people experience ongoing chest pain even after taking all available heart medications, and their large heart arteries are completely normal. This trial exists because current treatments don't adequately help these patients, and researchers believe this new implanted device could improve their symptoms and quality of life.
If you qualify, you would come to the hospital for a procedure where doctors insert the A-FLUX device through a vein—similar to how a pacemaker is placed, but less invasive. The procedure takes a few hours, and you would likely go home the same day or the next day. You would then return for follow-up visits at scheduled intervals to make sure the device is working well and to track whether your chest pain symptoms improve.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Netherlands
Poland
Spain